Chronic Kidney Disease

ACC 25 Late-Breaking Discussion: The SOUL Trial

Harriette Van Spall, Darren McGuire

Watch time: 20m 59s
Tirzepatide Shows Kidney Benefits in T2D: SURPASS Trials Analysis

Ellen Apperloo

Watch time: 6m 37s
AHA 24: 3 Trials That Will Change My Practice

Michelle Kittleson

Watch time: 10m 27s
AHA 24 Late-Breaking Discussion: REALIZE-K

Harriette Van Spall, Mikhail Kosiborod

Watch time: 22m 30s
AHA 24 Late-Breaking Discussion: The FLOW Trial

Harriette Van Spall,

Watch time: 16m 57s
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease

William Herrington

Watch time: 8m 11s
EASD 24: Prespecified Analysis from the SELECT Trial

Helen Colhoun

Watch time: 5m 37s
FLOW: Kidney, Cardiovascular, Mortality, Metabolic and Safety Results

Richard Pratley

Watch time: 6m 39s
ESC 24: FINE-HEART: Finerenone in HF & CKD

Muthiah Vaduganathan

Watch time: 4m 24s
ADA 24: FLOW Trial: Kidney Outcomes in Patients Treated with Semaglutide

Vlado Perkovic

Watch time: 5m 40s
Importance of Testing for CKD Among Patients With Type 2 Diabetes

Pam Taub, Nikolaus Marx

Watch time: 10m 51s
HFA 24: FINE-HEART: Design & Baseline Characteristics

Muthiah Vaduganathan

Watch time: 4m 40s

David Wheeler, Carol Pollock et al

Muthiah Vaduganathan

Sydney Tang et al

Andrew JS Coats, Stefan Anker

Importance of Testing for CKD Among Patients With Type 2 Diabetes

Pam Taub, Nikolaus Marx

Watch time: 10m 51s

James Burton

Watch time: 4m 58s (1 video)
HFA 24: FINE-HEART: Design & Baseline Characteristics

Muthiah Vaduganathan

Watch time: 4m 40s
ACC 22 Late-breaker Discussion: The DIAMOND Trial

Harriette Van Spall, Javed Butler, Faiez Zannad, et al

Watch time: 22m 47s
ERA 23: REVEAL-CKD: Underdiagnosis of CKD

Navdeep Tangri

Watch time: 3m 32s
ESC 24: FINE-HEART: Finerenone in HF & CKD

Muthiah Vaduganathan

Watch time: 4m 24s
Radcliffe & CardioNerds @AHA22: EMPA-Kidney: Empagliflozin & CV Outcomes in Patients with Chronic Kidney Disease

Kate Wilcox, David Preiss

Watch time: 18m 1s
CardioNerds @AHA23: Presidential Advisory on CKM Health

Ramy Doss, Chiadi Ndumele

Watch time: 14m 32s

Media

ACC 25 Late-Breaking Discussion: The SOUL Trial

Harriette Van Spall, Darren McGuire

Watch time: 20m 59s
Tirzepatide Shows Kidney Benefits in T2D: SURPASS Trials Analysis

Ellen Apperloo

Watch time: 6m 37s
ACC 22 Late-breaker Discussion: The DIAMOND Trial

Harriette Van Spall, Javed Butler, Faiez Zannad, et al

Watch time: 22m 47s
HFA 24: Timing of Cardio-Kidney Protection with SGLT2i

Muthiah Vaduganathan

Watch time: 5m 24s
ESC 24: FINE-HEART: Finerenone in HF & CKD

Muthiah Vaduganathan

Watch time: 4m 24s
AHA 24: 3 Trials That Will Change My Practice

Michelle Kittleson

Watch time: 10m 27s
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease

William Herrington

Watch time: 8m 11s
AHA 24 Late-Breaking Discussion: The FLOW Trial

Harriette Van Spall,

Watch time: 16m 57s
AHA 24 Late-Breaking Discussion: REALIZE-K

Harriette Van Spall, Mikhail Kosiborod

Watch time: 22m 30s

Andrew JS Coats, Stefan Anker

EASD 24: Prespecified Analysis from the SELECT Trial

Helen Colhoun

Watch time: 5m 37s

David Wheeler, Carol Pollock et al

Articles